Leadiant Recalls Subpotent Cystaran Ophthalmic Solution
Leadiant Biosciences is recalling 1,380 bottles of Cystaran ophthalmic solution because testing found decreased levels of the active ingredient.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class III, which indicates the product is unlikely to cause adverse health consequences. The hazard is a subpotent drug, which is a quality issue rather than a direct safety hazard like contamination or injury.
Plain-English summary
Leadiant Biosciences, Inc. is recalling 1,380 bottles of Cystaran (cysteamine hydrochloride) 0.44% ophthalmic solution. The recall was initiated because product testing identified a decreased level of the active ingredient, Cysteamine HCl, making the product subpotent.
The affected product is Lot #370655 with an expiration date of 10/31/2020. The bottles are 15 mL, sterile, and labeled for ophthalmic use only. The product was distributed in Pennsylvania and Italy.
Consumers should stop using the recalled product and contact their healthcare provider or pharmacist for further instructions.
The recalled product
- Product
- CYSTARAN (CYSTEAMINE HYDROCHLORIDE)
- Brand
- CYSTARAN
- Manufacturer
- Leadiant Biosciences, Inc.
- Category
- Drug — Ophthalmic Solution
- Hazard
- Affected units
- 1,380
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 370655
- Exp. 10/31/2020
Distribution
Distribution scope not specified by the agency.
Related recalls
Same brand · CYSTARAN
- ModerateLeadiant Recalls Subpotent Cystaran Ophthalmic Solution
FDA (Drugs) · 2018-04-25
- ModerateLeadiant Recalls Subpotent Cystaran Cysteamine Ophthalmic Solution
FDA (Drugs) · 2018-03-07
Same manufacturer · Leadiant Biosciences, Inc.
See all →- HighAbelcet Injectable Drug Recalled Due to Bacterial Contamination
FDA (Drugs) · 2023-02-22
Same hazard · subpotent drug
See all →- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- ModerateAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02